June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Fragment crystallizable (Fc) region results in an increased systemic exposure with no significant difference in intra-ocular pharmacokinetics
Author Affiliations & Notes
  • Jennifer Le Couter
    Tumor Biology and Angiogenesis, Genentech, Inc, San Francisco, CA
  • Kapil Gadkar
    Tumor Biology and Angiogenesis, Genentech, Inc, San Francisco, CA
  • J. Michael Elliott
    Tumor Biology and Angiogenesis, Genentech, Inc, San Francisco, CA
  • Thomas Lee
    Tumor Biology and Angiogenesis, Genentech, Inc, San Francisco, CA
  • Y. Gloria Meng
    Tumor Biology and Angiogenesis, Genentech, Inc, San Francisco, CA
  • Linda Zhang
    Tumor Biology and Angiogenesis, Genentech, Inc, San Francisco, CA
  • Margaret Kenrick
    Tumor Biology and Angiogenesis, Genentech, Inc, San Francisco, CA
  • Saileta Prabhu
    Tumor Biology and Angiogenesis, Genentech, Inc, San Francisco, CA
  • Justin Scheer
    Tumor Biology and Angiogenesis, Genentech, Inc, San Francisco, CA
  • Footnotes
    Commercial Relationships Jennifer Le Couter, Genentech, Inc. (E); Kapil Gadkar, Genentech (E); J. Michael Elliott, Genentech (E); Thomas Lee, None; Y. Gloria Meng, Genentech Inc (E), Roche (I); Linda Zhang, None; Margaret Kenrick, Genentech (E); Saileta Prabhu, Genentech (E); Justin Scheer, Genentech (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1967. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jennifer Le Couter, Kapil Gadkar, J. Michael Elliott, Thomas Lee, Y. Gloria Meng, Linda Zhang, Margaret Kenrick, Saileta Prabhu, Justin Scheer; Fragment crystallizable (Fc) region results in an increased systemic exposure with no significant difference in intra-ocular pharmacokinetics. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1967.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

The elimination pathways and pharmacokinetics (PK) of monoclonal antibodies (mAb) and antigen binding fragments following systemic administration are well characterized. Less is known about the elimination and PK of these protein drugs following intravitreal (ITV) administration. Molecules containing Fc region lead to higher systemic exposure due to recycling via the neonatal Fc receptor for IgG following ITV administration. We examined the effect of structure on the ocular and systemic PK of targeted and untargeted (directed against the gp120 glycoprotein expressed in the HIV viral envelope) sets of these protein drugs in rabbits in an effort to develop criteria for the selection of the most optimal format for the next generation of ocular therapeutics.

 
Methods
 

Protein drugs (Figure) were administered bilaterally by ITV injection (500 µg/50 µl/ eye) to male NZ rabbits. Each eye was analyzed independently. Quadruplicate blood and ocular tissues (vitreous and aqueous humor) were sampled over 28 days post-dose. Protein drug concentrations were determined by ELISA. Individual data points that appeared to have been affected by anti-therapeutic antibody (ATA) in ATA-positive animals were excluded from the analysis. Ocular and systemic PK data were analyzed using previously established compartmental PK models for protein drugs.

 
Results
 

Vitreous levels of Fab, double-Cys F(ab’)2 , single-Cys F(ab’)2, and mAb were not significantly different following ITV administration. However, serum PK profiles were significantly different between the Fab fragments and mAb. For example, the relative areas under the curve of the concentration-time profile for the anti-gp120 Fab, double-Cys F(ab')2 and single-Cys F(ab’)2 formats compared to IgG were 0.007, 0.03, and 0.008 respectively.

 
Conclusions
 

Protein drug structure did not appear to dramatically impact t1/2 in the vitreous in rabbits. As expected the systemic exposure levels of mAb were >100-fold higher than that of Fab, which lacks Fc region. Additionally, the apparent serum t1/2 of mAb was 3-fold longer than the Fab. Taken together, these data indicate that Fc region results in an increased systemic exposure and may also result in unwanted accumulation over long term dosing, with no obvious therapeutic benefit to treat ocular diseases.

  
Keywords: 688 retina • 763 vitreous  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×